Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids.

Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Abstract Text:

OBJECTIVES: To determine if intravenous high-dose "pulse" glucocorticoid therapy induced remission or reduced subsequent requirements for orally administered glucocorticoids in pemphigus vulgaris. DESIGN: Retrospective, case-controlled study. SETTING: Academic referral center. PATIENTS OR OTHER PARTICIPANTS: Fifteen patients, all of whom had pemphigus vulgaris, were included in the analysis. The group comprised all patients with pemphigus vulgaris seen during 11.5 years who did not initially respond to low doses (< 40 mg/d) of prednisone and who were followed up for at least 500 days after beginning treatment. INTERVENTIONS: One group received very high-dose intravenous pulse(s) of methylprednisolone sodium succinate (Solu-Medrol) (n = 9). The other group did not receive intravenous pulse therapy (n = 6). MAIN OUTCOME MEASURES: Glucocorticoid dose and status of disease. RESULTS: Patients treated with pulse therapy and control patients treated with conventional oral prednisone had similar initial disease severity. Six of the 9 patients who received pulse therapy showed improvement of their pemphigus vulgaris, and 4 of the 9 had discontinued all glucocorticoids and were in remission at mean (+/- SEM) 269 +/- 27 days. They have continued in remission without receiving prednisone for a mean of 714 +/- 142 days. Therapeutic benefit was seen in patients who received pulse therapy early or late after beginning glucocorticoid therapy. In contrast, none of the 6 control patients has achieved long-term remissions without therapy. All of the controls have had long courses of glucocorticoid therapy, with a mean of 1467 +/- 112 days of prednisone treatment. Overall, the mean (+/- SEM) prednisone dose between days 350 and 500 from onset of glucocorticoid therapy was 9.2 +/- 4.2 mg/d for those who received pulse therapy vs 21.0 +/- 3.3 mg/d (P < .05) for those who did not (unpaired 2-tailed t test). CONCLUSIONS: High-dose pulse administration of glucocorticoids is a potentially effective therapy to be considered in the treatment of patients with severe pemphigus vulgaris. Similar patients treated with conventional orally administered doses of prednisone had protracted courses requiring years of glucocorticoid therapy with no long-term remissions.

Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Publishing Authors By Initials

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Archives of dermatology

VOLUME: 132

Page Numbers: 1435-9

Journal Abbreviation: Arch Dermatol

ISSN: 0003-987X

DAY: 17

MONTH: Dec

YEAR: 1996

Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372433

Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Information

Substance Name: Methylprednisolone

Registry Number: 83-43-2

Grant and Affiliation Information for Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids.

AFFILIATION: Department of Dermatology, University of Pennsylvania, Philadelphia, USA.

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Arch Dermatol

REFSOURCE: Arch Dermatol. 1996 Dec;132(12):1499-502

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids Related Publications

• Activation of autoimmunity following use of immunostimulatory herbal supplements.
• CONTINUING EDUCATION: Is It Valid?
• Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study.
• Cutaneous lupus: insights into pathogenesis and disease classification.
• Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.
• Dermatologic therapeutics: thalidomide. A practical guide.
• Dermatology vignette. Pseudoporphyria caused by NSAIDs.
• Development of outcome measures for autoimmune dermatoses.
• Failure of physiologic doses of pure UVA or UVB to induce lesions in photosensitive cutaneous lupus erythematosus: implications for phototesting.
• Lizard ecology: evidence of competition.
• Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center.
• Numerous erythematous truncal plaques. Multiple basal cell carcinomas associated with arsenic ingestion.
• Pathophysiology of cutaneous lupus erythematosus.
• RISK MANAGEMENT FOR CHIROPRACTORS AND OSTEOPATHS: Neck Manipulation & Vertebrobasilar Stroke.
• Regeneration of sulfur-fouled bimetallic Pd-based catalysts.
• Reliability of fMRI during a Continuous Motor Task: Assessment of Analysis Techniques.
• Risk Management for Chiropractors and Osteopaths. Informed consent: A Common Law Requirement.
• Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions.
• The cutaneous lupus erythematosus disease activity and severity index: Expansion for rheumatology and dermatology.
• The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus.
• Treatment of bullous pemphigoid with topical corticosteroids: review of a randomized controlled trial.
• Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids.
• Ulcerating skin lesions and arthritis after a crab bite.
• What is new in the treatment of steroid-induced osteoporosis?
• What is new in the treatment of steroid-induced osteoporosis?
• [Effect of malachite green on metabolism, especially on the enzymes of the respiratory chain in rats and their relation to the problem of abnormalities and carcinogenesis.]
• [Incidence of hereditary disorders caused by prolonged malachite green poisoning in rats; a contribution to chemogenesis.]
• [Methods of experimental research on cancer and its significance in practical medicine.]
• [The effect of malachite green on the growth of Walker rat carcinoma and Ehrlich mouse ascites tumor.]
• [The history of medicine. Richard Werth (1850-1918)]